Phase 3 Pridopidine Trial for ALS Begins Enrollment
7d
Developing
2
A Phase 3 clinical trial of pridopidine has begun enrolling people with ALS to test whether the drug can slow disease progression. Separately, Columbia University researchers report promising early results from an experimental antisense‑style therapy targeting a rare FUS mutation — including one patient whose EMG abnormalities normalized and who remains symptom‑free three years later — prompting optimism from Dr. Neil Shneider and supporting Columbia’s Silence ALS initiative to develop individualized gene‑based treatments.